Boehringer takes another stab at liver disease research, in deal with Ribo Life Science

4 January 2024
boehringer_building_large

China’s Suzhou Ribo Life Science and its Ribocure unit have entered into collaboration with German family-owned pharma major Boehringer Ingelheim to develop novel treatments for non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

The partnership brings together Ribo's leading experience in the discovery and clinical development of small interfering RNA (siRNA) therapeutics with Boehringer's commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases (CRM).

Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes by silencing their messenger RNAs (mRNAs). This approach has the potential to treat diseases addressing previously inaccessible drug targets.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical